Please login to the form below

Not currently logged in

Opdivo plus chemotherapy increases response in pre-surgery NSCLC patients

Combination increases complete response rate to 24% compared to chemotherapy alone

Bristol Myers Squibb’s PD-1 inhibitor Opdivo has scored a new win in the pre-surgery, non-small cell lung cancer (NSCLC) setting.

Data presented at the virtual American Association for Cancer Research (AACR) annual meeting showcased results from the CheckMate-816 study, which evaluated Opdivo (nivolumab) plus chemotherapy in patients with early-stage NSCLC before surgery.

The primary endpoints of the study were pathological complete response (pCR), defined as no residual viable tumour in the resected lung specimen and the sampled lymph node after surgery and event-free survival (EFS).

Researchers found that Opdivo plus chemotherapy increased the pCR rate to 24% in the intent-to-treat population, compared to just 2.2% of patient treated with chemotherapy alone.

In patients with resection, the pCR rate increased further to 30.5% for those receiving the Opdivo/chemotherapy combination, compared to 3.2% in patients receiving chemotherapy alone.

The improvement in pCR was consistent across subgroups, including disease stage, NSCLC subtype, PD-L1 status, tumour mutational burden status and gender.

The administration of Opdivo also did not affect patients’ eligibility to receive definitive surgery – 83.2% in the Opdivo/chemotherapy arm compared to 75.4% of patients in the chemotherapy alone arm.

In addition, the pre-surgery objective response rate on imaging in the Opdivo combination arm was 53.6% compared with 37.4% in the chemotherapy arm, with radiographic down-staging rates of 30.7% compared with 23.5% respectively.

“CheckMate-816 is the first phase 3 trial to show a benefit of neoadjuvant chemotherapy plus chemo and this has the potential to represent a new neoadjuvant treatment option for patients with early-stage, resectable non-small cell lung cancer,” said Patrick Forde, associate professor, Sidney Kimmel Comprehensive Cancer Center and Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University.

Although Merck & Co’s rival checkpoint inhibitor Keytruda (pembrolizumab) is dominant in the NSCLC setting, it does not possess similar results in the pre-surgery, neoadjuvant setting.

With the CheckMate-816 results in hand, Opdivo could gain an advantage over Keytruda in the early-stage setting, although BMS did not disclose its plans for regulatory approval during the AACR presentation.

However, Forde did note that the study will continue to mature for data from the EFS co-primary endpoint – again, the timeline for this was not disclosed.

Article by
Lucy Parsons

12th April 2021

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
OPEN Health

OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....